HRP20100568T1 - Rekombinantno modificiran plazmin - Google Patents
Rekombinantno modificiran plazmin Download PDFInfo
- Publication number
- HRP20100568T1 HRP20100568T1 HR20100568T HRP20100568T HRP20100568T1 HR P20100568 T1 HRP20100568 T1 HR P20100568T1 HR 20100568 T HR20100568 T HR 20100568T HR P20100568 T HRP20100568 T HR P20100568T HR P20100568 T1 HRP20100568 T1 HR P20100568T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- seq
- polynucleotide
- lysine
- plasmin
- Prior art date
Links
- 229940012957 plasmin Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims abstract 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 22
- 102000040430 polynucleotide Human genes 0.000 claims abstract 11
- 108091033319 polynucleotide Proteins 0.000 claims abstract 11
- 239000002157 polynucleotide Substances 0.000 claims abstract 11
- 239000004472 Lysine Substances 0.000 claims abstract 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract 5
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 claims abstract 4
- 239000002773 nucleotide Substances 0.000 claims abstract 3
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 3
- 108010022999 Serine Proteases Proteins 0.000 claims abstract 2
- 102000012479 Serine Proteases Human genes 0.000 claims abstract 2
- 230000004913 activation Effects 0.000 claims abstract 2
- 210000004899 c-terminal region Anatomy 0.000 claims abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 230000005764 inhibitory process Effects 0.000 claims 4
- 108010015052 miniplasmin Proteins 0.000 claims 4
- 229920000936 Agarose Polymers 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102000009123 Fibrin Human genes 0.000 claims 2
- 108010073385 Fibrin Proteins 0.000 claims 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims 2
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229950003499 fibrin Drugs 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 230000003480 fibrinolytic effect Effects 0.000 claims 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56447204P | 2004-04-22 | 2004-04-22 | |
| PCT/US2005/013562 WO2005105990A2 (en) | 2004-04-22 | 2005-04-21 | Recombinantly modified plasmin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100568T1 true HRP20100568T1 (hr) | 2010-11-30 |
Family
ID=34982338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100568T HRP20100568T1 (hr) | 2004-04-22 | 2010-10-19 | Rekombinantno modificiran plazmin |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8034913B2 (da) |
| EP (2) | EP1740698B1 (da) |
| JP (1) | JP5026254B2 (da) |
| KR (1) | KR101161819B1 (da) |
| CN (2) | CN102660564B (da) |
| AT (1) | ATE476502T1 (da) |
| AU (1) | AU2005238464B2 (da) |
| BR (1) | BRPI0510063B8 (da) |
| CA (1) | CA2563675C (da) |
| CY (1) | CY1111650T1 (da) |
| DE (1) | DE602005022692D1 (da) |
| DK (1) | DK1740698T3 (da) |
| EA (1) | EA010784B1 (da) |
| ES (2) | ES2534744T3 (da) |
| HK (3) | HK1099341A1 (da) |
| HR (1) | HRP20100568T1 (da) |
| IL (1) | IL178343A (da) |
| MA (1) | MA28590B1 (da) |
| MX (1) | MXPA06012236A (da) |
| NO (1) | NO338542B1 (da) |
| NZ (1) | NZ550250A (da) |
| PL (2) | PL2246417T3 (da) |
| PT (2) | PT1740698E (da) |
| RS (1) | RS51623B (da) |
| SI (1) | SI1740698T1 (da) |
| TN (1) | TNSN06332A1 (da) |
| WO (1) | WO2005105990A2 (da) |
| ZA (1) | ZA200608498B (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2555609A1 (en) | 2004-02-11 | 2005-08-25 | Biolex, Inc. | Expression of plasminogen and microplasminogen in duckweed |
| KR101161819B1 (ko) | 2004-04-22 | 2012-07-03 | 테일크리스 바이오쎄러퓨틱스 아이엔씨. | 재조합적으로 변형된 플라스민 |
| US8231869B2 (en) * | 2005-10-20 | 2012-07-31 | Grifols Therapeutics Inc. | Recombinant plasmin for opthalmic indications |
| KR100888022B1 (ko) * | 2006-12-21 | 2009-03-09 | 재단법인 목암생명공학연구소 | 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8Ｆｃ |
| EP2220221B1 (en) * | 2007-11-29 | 2014-12-31 | Grifols Therapeutics Inc. | Recombinantly modified plasmin |
| BRPI0913397B8 (pt) | 2008-06-04 | 2021-05-25 | Grifols Therapeutics Inc | método para preparar plasmina |
| JP5789521B2 (ja) | 2009-03-03 | 2015-10-07 | グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン |
| MX2012000475A (es) | 2009-07-10 | 2012-03-26 | Thrombogenics Nv | Variantes de plasminogeno y plasmina. |
| EP2480249B1 (en) | 2009-08-28 | 2015-01-28 | ThromboGenics N.V. | Plasmin for the treatment of filtration failure after trabeculectomy |
| EP2661493B1 (en) | 2011-01-05 | 2016-03-30 | ThromboGenics N.V. | Plasminogen and plasmin variants |
| CN103764163A (zh) | 2011-08-12 | 2014-04-30 | 斯路姆基因公司 | 纤溶酶原和纤溶酶变体 |
| US10709771B2 (en) * | 2015-12-18 | 2020-07-14 | Talengen International Limited | Method for preventing or treating diabetic retinopathy |
| WO2018107686A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种治疗动脉粥样硬化及其并发症的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| CN108210904A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 治疗动脉粥样硬化及其并发症的药物及其用途 |
| WO2018107705A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种促进胰岛素分泌的方法 |
| CN115427704A (zh) | 2020-04-13 | 2022-12-02 | 株式会社F.C.C. | 动力传递装置 |
| CN115697385A (zh) * | 2020-05-11 | 2023-02-03 | 泰伦基国际有限公司 | 一种治疗脊髓性肌萎缩症的方法和药物 |
| US20240299506A1 (en) | 2020-11-25 | 2024-09-12 | Grifols Worldwide Operations Limited | Wound healing |
| US11964004B2 (en) * | 2021-03-31 | 2024-04-23 | Shenzhen Bay Laboratory | Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof |
| WO2024018051A1 (en) | 2022-07-22 | 2024-01-25 | Grifols Worldwide Operations Limited | Stable plasmin compositions for organ preservation and reconditioning |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4652639A (en) | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US5149533A (en) * | 1987-06-04 | 1992-09-22 | Zymogenetics, Inc. | Modified t-PA with kringle-/replaced by another kringle |
| US4774087A (en) | 1987-08-14 | 1988-09-27 | Northwestern University | Micro-size fibrinolytic plasmin |
| ES2120949T4 (es) | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo. |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US6613508B1 (en) | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
| US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
| DE69701671T3 (de) | 1996-01-23 | 2006-08-17 | Qiagen Genomics, Inc., Bothell | Verfahren und zusammenstellungen zur sequenzbestimmung von nukleinsäuremolekülen |
| JPH10158300A (ja) | 1996-11-28 | 1998-06-16 | Suzuki Motor Corp | 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法 |
| EP1000176A1 (en) | 1997-07-22 | 2000-05-17 | Rapigene, Inc. | Computer method and system for correlating sequencing data by ms |
| US6538103B1 (en) | 1998-07-14 | 2003-03-25 | Bristol--Myers Squibb Company | Lysine binding fragments of angiostatin |
| DK1117437T3 (da) | 1998-09-29 | 2007-04-10 | Leuven Res & Dev Vzw | Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde |
| US6969515B2 (en) | 1999-11-13 | 2005-11-29 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US6355243B1 (en) | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
| US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| JP2004509609A (ja) | 2000-06-02 | 2004-04-02 | ブルー ヘロン バイオテクノロジー インコーポレイテッド | 合成二本鎖オリゴヌクレオチドの配列忠実度を改善するための方法 |
| AU2002218890A1 (en) | 2000-12-21 | 2002-07-01 | Thromb-X N.V. | A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell |
| AU2002357249A1 (en) | 2001-12-13 | 2003-07-09 | Blue Heron Biotechnology, Inc. | Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins |
| US7776026B2 (en) | 2002-02-06 | 2010-08-17 | Nuvue Technologies, Inc. | Method for vitreous liquefaction |
| US20050124036A1 (en) | 2002-02-06 | 2005-06-09 | Rudy Susilo | Method for producing recombinant proteins in micro-organisms |
| GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
| KR101161819B1 (ko) | 2004-04-22 | 2012-07-03 | 테일크리스 바이오쎄러퓨틱스 아이엔씨. | 재조합적으로 변형된 플라스민 |
| US8231869B2 (en) | 2005-10-20 | 2012-07-31 | Grifols Therapeutics Inc. | Recombinant plasmin for opthalmic indications |
| EP2220221B1 (en) * | 2007-11-29 | 2014-12-31 | Grifols Therapeutics Inc. | Recombinantly modified plasmin |
-
2005
- 2005-04-21 KR KR1020067024427A patent/KR101161819B1/ko active IP Right Grant
- 2005-04-21 DE DE602005022692T patent/DE602005022692D1/de active Active
- 2005-04-21 ES ES10166134.6T patent/ES2534744T3/es active Active
- 2005-04-21 CN CN2012101142890A patent/CN102660564B/zh not_active Expired - Fee Related
- 2005-04-21 SI SI200531131T patent/SI1740698T1/sl unknown
- 2005-04-21 PT PT05737862T patent/PT1740698E/pt unknown
- 2005-04-21 EP EP05737862A patent/EP1740698B1/en active Active
- 2005-04-21 DK DK05737862.2T patent/DK1740698T3/da active
- 2005-04-21 AT AT05737862T patent/ATE476502T1/de active
- 2005-04-21 PL PL10166134T patent/PL2246417T3/pl unknown
- 2005-04-21 US US11/568,023 patent/US8034913B2/en not_active Expired - Fee Related
- 2005-04-21 WO PCT/US2005/013562 patent/WO2005105990A2/en active Application Filing
- 2005-04-21 PT PT101661346T patent/PT2246417E/pt unknown
- 2005-04-21 BR BRPI0510063A patent/BRPI0510063B8/pt not_active IP Right Cessation
- 2005-04-21 CN CNA2005800155389A patent/CN1961070A/zh active Pending
- 2005-04-21 AU AU2005238464A patent/AU2005238464B2/en not_active Ceased
- 2005-04-21 EA EA200601950A patent/EA010784B1/ru not_active IP Right Cessation
- 2005-04-21 EP EP10166134.6A patent/EP2246417B1/en active Active
- 2005-04-21 ES ES05737862T patent/ES2349555T3/es active Active
- 2005-04-21 RS RS20100473A patent/RS51623B/en unknown
- 2005-04-21 PL PL05737862T patent/PL1740698T3/pl unknown
- 2005-04-21 CA CA2563675A patent/CA2563675C/en active Active
- 2005-04-21 NZ NZ550250A patent/NZ550250A/en not_active IP Right Cessation
- 2005-04-21 MX MXPA06012236A patent/MXPA06012236A/es active IP Right Grant
- 2005-04-21 JP JP2007509616A patent/JP5026254B2/ja not_active Expired - Fee Related
-
2006
- 2006-09-27 IL IL178343A patent/IL178343A/en active IP Right Grant
- 2006-10-11 ZA ZA200608498A patent/ZA200608498B/en unknown
- 2006-10-13 TN TNP2006000332A patent/TNSN06332A1/en unknown
- 2006-11-03 NO NO20065050A patent/NO338542B1/no not_active IP Right Cessation
- 2006-11-20 MA MA29466A patent/MA28590B1/fr unknown
-
2007
- 2007-06-15 HK HK07106503.0A patent/HK1099341A1/xx not_active IP Right Cessation
-
2010
- 2010-10-18 CY CY20101100930T patent/CY1111650T1/el unknown
- 2010-10-19 HR HR20100568T patent/HRP20100568T1/hr unknown
-
2011
- 2011-04-28 HK HK11104278.2A patent/HK1150242A1/xx not_active IP Right Cessation
- 2011-09-01 US US13/223,373 patent/US8420079B2/en active Active
-
2013
- 2013-03-12 HK HK13103040.9A patent/HK1175812A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100568T1 (hr) | Rekombinantno modificiran plazmin | |
| Rodrigues et al. | Structural and functional characterization of neuwiedase, a nonhemorrhagic fibrin (ogen) olytic metalloprotease from Bothrops neuwiedi snake venom | |
| Várallyay et al. | Two mutations in rat trypsin confer resistance against autolysis | |
| NZ593837A (en) | Recombinantly modified plasmin | |
| CA2254647C (en) | Chimeric serine proteases | |
| Lengyel et al. | Affinity purification of recombinant trypsinogen using immobilized ecotin | |
| Fujimura et al. | Primary structure and autoproteolysis of brevilysin H6 from the venom of Gloydius halys brevicaudus | |
| Park et al. | Cloning and characterization of novel disintegrins from Agkistrodon halys venom | |
| Hahn et al. | Purification and characterization of a serine protease with fibrinolytic activity from Tenodera sinensis (praying mantis) | |
| Averna et al. | Phosphorylation of rat brain calpastatins by protein kinase C | |
| Zhou et al. | Purification, cloning and biological characterization of a novel disintegrin from Trimeresurus jerdonii venom | |
| Heil et al. | Differences in the inhibition of coagulation factor XIII-A from animal species revealed by Michael Acceptor–and thioimidazol based blockers | |
| Imajoh et al. | Fragment of an endogenous inhibitor produced in Escherichia coli for calcium-activated neutral protease (CANP) retains an inhibitory activity | |
| Terada et al. | Purification and amino acid sequence of brevilysin L6, a non-hemorrhagic metalloprotease from Agkistrodon halys brevicaudus venom | |
| PARk et al. | Purification and biochemical characterization of a novel glutamyl endopeptidase secreted by a clinical isolate of Staphylococcus aureus | |
| Zhang et al. | Functional properties of a recombinant chimeric plasminogen activator with platelet-targeted fibrinolytic and anticoagulant potential | |
| Dahiya et al. | Enhanced plasminogen activation by staphylokinase in the presence of streptokinase β/βγ domains: plasminogen kringles play a role | |
| Chen et al. | A novel high molecular weight metalloproteinase cleaves fragment F1 of activated human prothrombin | |
| Zhong et al. | Vascular endothelial growth factor from Trimeresurus jerdonii venom specifically binds to VEGFR-2 | |
| Friedrich et al. | An isopeptide bond splitting enzyme from Hirudo medicinalis similar to γ‐glutamyl transpeptidase | |
| Balaban et al. | Isolation and characterisation of Bacillus amyloliquefaciens H2 glutamyl endopeptidase that is secreted in stationary phase of culture growth | |
| DK0819173T3 (da) | Mutant af inhibitoren af Erythrina caffra-typen og anvendelse deraf til oprensning af serinproteaser | |
| Zhang et al. | Expression and characterization of ARSP1 from Eisenia fetida | |
| Koh et al. | Characterization and cDNA cloning of a platelet aggregation inhibitor | |
| Waugh et al. | Crystallization and analysis of serine proteases with ecotin |